Allograft reconstruction of the extensor mechanism after resection of soft tissue sarcoma

Allograft reconstruction of the extensor mechanism after resection of soft tissue sarcoma: a case series

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN63060594

Enrollment

Registered

2017-12-04

Start date

2015-01-01

Completion date

Unknown

Last updated

2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Soft tissue tumors around the knee joint Musculoskeletal Diseases Soft tissue tumors around the knee joint

Interventions

The database is retrospectively searched for patients who underwent a resection of a soft tissue sarcoma involving the extensor mechanism. From these patients informed consent is obtained. In addition

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have undergone a surgical resection of a soft tissue sarcoma affecting the quadriceps tendon, the patella and / or the patellar tendon without apparent joint involvement 2. Patients ranged from 34 to 68 years

Exclusion criteria

Exclusion criteria: Patients with involvement of the joint space needed an extra-articular knee resection and an allograft prosthetic composite reconstruction.

Design outcomes

Primary

Measure	Time frame
1. Knee function the active range of motion, active flexion and extension lag is measured using the International Society of Limb Salvage (ISOLS) score at yearly follow ups and using data from reviewing the patient charts. 2. Local recurrence rate is measured using Kaplan Meier curve for local recurrence free survival for 10 years. The presence of a local recurrence was detected by careful clinical examination and radiologic controls. 3. Surgical complication rate is measured by registering all the revision surgeries of the included patients during the observational time.	—

Measure

Time frame

1. Knee function the active range of motion, active flexion and extension lag is measured using the International Society of Limb Salvage (ISOLS) score at yearly follow ups and using data from reviewing the patient charts. 2. Local recurrence rate is measured using Kaplan Meier curve for local recurrence free survival for 10 years. The presence of a local recurrence was detected by careful clinical examination and radiologic controls. 3. Surgical complication rate is measured by registering all the revision surgeries of the included patients during the observational time.

—

Secondary

Measure	Time frame
1. Metastatic disease survival is measured using Kaplan Meier curve for metastasis free survival for 10 years. The presence of a metastasis was detected by careful clinical examination and CT chest. 2. Overall disease specific survival is measured using Kaplan Meier curve for overall survival for 10 years. 3. Functional outcome is measured by measuring the active range of motion (°), active flexion and extension lag at the last follow up. The International Society of Limb Salvage (ISOLS) score was calculated at the last follow up.	—

Measure

Time frame

1. Metastatic disease survival is measured using Kaplan Meier curve for metastasis free survival for 10 years. The presence of a metastasis was detected by careful clinical examination and CT chest. 2. Overall disease specific survival is measured using Kaplan Meier curve for overall survival for 10 years. 3. Functional outcome is measured by measuring the active range of motion (°), active flexion and extension lag at the last follow up. The International Society of Limb Salvage (ISOLS) score was calculated at the last follow up.

—

Countries

Italy, Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 25, 2026